BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era
June 29, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...
Mr. Robert W. Cook, Seasoned Biotech Executive, Joins RenovaCare as Chief Financial Officer and Board Secretary
June 16, 2020 08:30 ET
|
RenovaCare, Inc.
ROSELAND, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
RenovaCare Appoints Chief Medical Officer, Dr. Jo Ellen Schweinle, Former Sr. Medical Officer at U.S. Dept. of Health and Human Services
June 10, 2020 08:36 ET
|
RenovaCare, Inc.
ROSELAND, N.J., June 10, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
RenovaCare Strengthens FDA Program with Leading U.S. Regulatory Group and Significant Investment
May 28, 2020 08:30 ET
|
RenovaCare, Inc.
ROSELAND, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
RenovaCare Appoints Founding Director of BARDA Dr. Robin A. Robinson to Chief Scientific Officer
May 26, 2020 08:30 ET
|
RenovaCare, Inc.
ROSELAND, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration...
BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
May 15, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported...
Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation
May 12, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure
May 05, 2020 07:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BIOCARDIA REPORTS 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
April 09, 2020 14:03 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...
BIOCARDIA ANNOUNCES POSITIVE DSMB RECOMMENDATION TO CONTINUE PHASE III PIVOTAL CARDIAMP HEART FAILURE STUDY, AS PLANNED
March 31, 2020 08:00 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...